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Abstract: To diagnose and treat early-stage (preclinical) Alzheimer’s disease (AD) patients, we need
body-fluid-based biomarkers that reflect the processes that occur in this stage, but current knowledge
on associated processes is lacking. As human studies on (possible) onset and early-stage AD would
be extremely expensive and time-consuming, we investigate the potential value of animal AD models
to help to fill this knowledge gap. We provide a comprehensive overview of processes associated
with AD pathogenesis and biomarkers, current knowledge on AD-related biomarkers derived from
on human and animal brains and body fluids, comparisons of biomarkers obtained in human AD and
frequently used animal AD models, and emerging body-fluid-based biomarkers. In human studies,
amyloid beta (Aβ), hyperphosphorylated tau (P-tau), total tau (T-tau), neurogranin, SNAP-25, glial
fibrillary acidic protein (GFAP), YKL-40, and especially neurofilament light (NfL) are frequently
measured. In animal studies, the emphasis has been mostly on Aβ. Although a direct comparison
between human (familial and sporadic) AD and (mostly genetic) animal AD models cannot be made,
still, in brain, cerebrospinal fluid (CSF), and blood, a majority of similar trends are observed for
human AD stage and animal AD model life stage. This indicates the potential value of animal AD
models in understanding of the onset and early stage of AD. Moreover, animal studies can be smartly
designed to provide mechanistic information on the interrelationships between the different AD
processes in a longitudinal fashion and may also include the combinations of different conditions that
may reflect comorbidities in human AD, according to the Mastermind Research approach.
Keywords: Alzheimer’s disease; early diagnosis; body fluids; biomarker; animal models
1. Introduction
Alzheimer’s disease (AD) is a complex progressive neurodegenerative disorder and is the most
common cause of dementia. AD can roughly be divided into two types: familial AD (~5% of total AD
patients) and late-onset (LOAD) or sporadic AD (~95% of total AD patients). Familial AD is caused
Int. J. Mol. Sci. 2020, 21, 3158; doi:10.3390/ijms21093158 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 3158 2 of 27
by mutations in either the APP gene or in the genes encoding presenilin 1 (PSEN1) or presenilin 2
(PSEN2), which are essential components of the γ-secretase complex [1]. These mutations lead to the
elevation of total amyloid beta (Aβ), a higher Aβ1-42/Aβ1-40 ratio, and Aβ aggregation [2]. In sporadic
AD, the disturbance of Aβ clearance mechanisms is thought to be the major contribution to Aβ
accumulation in the brain, but a (causal) relationship is not fully understood [3,4]. In contrast, it is
well-established that an increased frequency of the ApoE ε4 allele indicates increased risk to develop
AD [5,6]. The ApoE ε4 allele plays an important role in several AD-related processes, such as the
oxidative stress response [7], synaptic loss [8], Aβ accumulation [9], and ApoE/LRP1-mediated Aβ
clearance [4]. Studies with transgenic APOE−/− mice showed that these mice develop blood–brain
barrier (BBB) breakdown. APOE4 drives the matrix metalloproteinase 9 (MPP-9)-mediated BBB
dysfunction that finally contributes to disturbed influx/efflux of Aβ across the BBB [10].
Different stages in AD progression have been defined [11,12]: the first is the preclinical stage or
asymptomatic stage. It occurs between the earliest pathogenic events of AD and the first appearance
of specific cognitive changes, which are different from the changes observed in normal ageing.
This asymptomatic stage might take many years to develop [13,14]. The second stage is the prodromal
stage and is defined by mild cognitive impairment (MCI). In this stage, cognitive changes and amnestic
symptoms are present. Importantly, MCI is not selective for AD as not all individuals with MCI
develop AD, but individuals with MCI have an increased risk of developing AD or other forms of
dementia [15]. In the third and final stage of AD, brain Aβ plaques and neurofibrillary tau tangles
(NFTs) may appear on imaging tests of the brain. Individuals at this stage lose control of physical
functions and depend on others for care. They sleep more often and are unable to communicate or
even recognize their loved ones.
Currently there is no treatment for AD other than some symptomatic treatments that do not slow
down or halt AD progression. It is thought that treatment options for AD modification will be more
effective during the preclinical stage [11,16–19]. Postmortem autopsy of the AD brain, which then
shows atrophy, neuronal loss, Aβ plaques, and NFTs, is the only certain AD diagnosis [20,21]. During
life, clinical evaluation of AD considers cognitive deficits by neuropsychological assessments and
measurements of Aβ1-42 and total tau (T-tau) in cerebrospinal fluid (CSF) [22,23]. The CSF Aβ1-42 level
and Aβ1-42/Aβ1-40 ratio have now been widely accepted as valid indicators of brain accumulation
of Aβ [24]. Furthermore, imaging techniques like magnetic resonance imaging (MRI) and positron
emission tomography (PET) are used to obtain information on Aβ plaques and the size of the brain
and to rule out possible other causes of dementia.
The diagnosis of early AD is currently not yet possible, and there is a great need for information
regarding and understanding of the processes that are involved in the onset and early stages of AD.
Currently, subjective cognitive decline (SCD) epidemiological data provide evidence that the risk
for mild cognitive impairment and dementia is increased in individuals with SCD [25], but we do
not yet know what mechanism drives the body toward developing AD. Thus, we have a gap in our
understanding of onset and early development of AD.
The problem challenge facing this field of research is that of obtaining more mechanistic information
on the time course and interrelationships of the rate and extent of processes that drive the onset and
early development of human AD. In humans, there is the possibility for monitoring blood levels of
multiple body compounds (potential biomarkers) in cohort. Many such cohort measurements are
currently ongoing. Although we might learn a lot from such studies, there are crucial limitations.
First, for detecting early changes in body processes that may lead to AD, plasma information is not
sufficient, as the levels of body compounds may result in many disturbances not necessarily connected
to AD onset. Information on the brain might be provided by what can be detected using imaging
techniques. However, imaging techniques are very costly and will not be used in all subjects, let alone
in each human subject at each year of follow-up. Thus, human subjects will have developed (significant
indicators of) AD before the information of the human subject in relation to AD progression can be
obtained. As AD progresses slowly, this will take years at least. In other words, such studies at
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best would be very expensive and time-consuming. Therefore, we look to additional, alternative
approaches to help solve the problem.
Animal models of AD do not really reflect AD in humans. Human AD is familial for only about
5% of cases, while most animal AD models are based on mutations in APP, PSEN1, and/or PSEN2
genes. However, the “artificial” AD in animal models of AD might still provide us with information
that can be helpful to unravel processes associated with development of AD. This could be helpful in
guiding research in humans, focusing on what can be learned from body fluids that can readily be
obtained from humans. In animal AD models we can also investigate the influence of combinations of
conditions in a well-defined setting [26]. As an example, in mice, it was shown that a combination of
ApoE deficiency and high-fat diet, but not these conditions on their own, leads to BBB disruption and
neuropathology [27], as would be useful in research on comorbidities in AD.
In this review, we first provide an overview of pathophysiological hypotheses/mechanisms
and underlying processes that are thought to play a role in the onset and progression of AD. Then,
we summarize published data on the frequently used compounds (biomarkers) in AD research, namely
Aβ1-40, Aβ1-42, hyperphosphorylated tau (P-tau), T-tau, neurogranin, SNAP-25, glial fibrillary acidic
protein (GFAP), YKL-40, and neurofilament light (NfL), and their presence/concentrations in brain
and body fluids (blood/serum/plasma and CSF) in human AD subjects and controls and in frequently
used animal models of AD. Next, we compare the human and animal data to identify similarities.
Furthermore, we include emerging new biomarkers that can be measured in body fluids, as these could
extend our knowledge on changes in body fluids in AD, to help in identifying composite biomarker
panels that indicate the stage of AD and could be used in AD stage diagnosis.
Finally, we discuss the potential value of animal AD models in helping to generate better insights
in processes involved in onset and progression of AD, their interactions, and the possibility of designing
experiments with well-defined conditions (e.g., to include comorbidities) to understand the influence
of these conditions and combinations thereof.
2. Pathophysiological Hypotheses and Associated Biomarkers
To effectively identify and validate biomarkers of AD, knowledge about the underlying molecular
pathogenesis of AD is critical. A comprehensive overview of all pathological processes is needed
to understand the disease. As AD is a complex disease, in which multiple processes are known to
play a role, different hypotheses exists focusing on the different processes which (might) play a role
in AD [28–30]. Overall, these are briefly described in Supplementary Material 1, and the timeline is
displayed in Figure 1.
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Some recent findings seem to provide new hypotheses. These include changes in the functioning
of the endocrine pathway and the vagus nerve [38] as well as in the gut-microbiome-derived
metabolites [29]. In addition, not so long ago, glucose hypo-metabolism was found as an early
pathogenic event in the prodromal phase of AD and was associated with cognitive and functional
decline [39], which makes glucose metabolism brain-imaging 2-deoxy-2-fluorine-18-fluoro-d-glucose
positron emission tomography (18FDG-PET) a valuable indicator for the diagnosis of neurodegenerative
diseases that cause dementia, including AD [40].
Cerebral insulin resistance has been accepted as contributing to the neurodegenerative process in
AD by activating oxidative stress, cytokine production, and apoptotic process [41]. It is also the link
between sporadic AD and its risk factor of diabetes [42]. Furthermore, age-related decline in the ability
of glucose to cross the BBB might lead to the production of Aβplaques and tau-containing neurofibrillary
tangles (neuro-energetic hypothesis) [43]. Moreover, insulin resistance in type 2 diabetes mellitus and
obesity is a risk factor for AD, as insulin resistance might contribute to neurodegeneration [44].
Interestingly, type 2 diabetes mellitus animals develop accumulation of AD pathologies like
Aβ plaques and tau phosphorylation [45]. Furthermore, insulin has effects on Aβ production and
clearance via the MEK-ERK pathway. Aβ, in turn, is found to induce the removal of cell surface insulin
receptors [46]. The contribution of mitochondria in the pathogenesis of AD has also been studied
(which relates to oxidative stress); however, their exact role and place in the disease cascade is still not
fully known [47]. Furthermore, the disruption of neural circuits has also been studied in relation to AD.
Again, the question arises as to whether the disruption of neuronal circuits is a cause or consequence in
AD pathology; however, impairment of neuronal circuits is already found in early stages of the disease.
Interestingly, some aspects of AD-related neuronal dysfunction reported in mice are quite similar to
the human situation [48].
Overall, there are multiple mechanisms that possibly contribute to AD, and these have led to
the investigation of a broad range of different biomarkers (Table 1) that are related to these different
processes, with neuronal degeneration as a final outcome [49–60]. As indicated, biomarkers are
urgently needed to provide information regarding the pathobiology of AD in order to find a cure and
to diagnose AD, preferably in the preclinical stage, with minimal burden for the patient and minimal
costs. Biomarkers obtained from body fluids like CSF and blood are therefore needed. Preferably,
these markers will provide information in the preclinical stage.
Table 1. Alzheimer’s disease (AD)-related processes and the corresponding potential body-fluid-based
biomarkers. It should be noted that some of these compounds are not specific for AD but may be of
value by having a role in AD pathology.
Process Remarks Related (Potential)Body-Fluid-Based Biomarkers Reference
Decreased cholinergic
transmission







of tau protein resulting
in hyperphosphorylation
of the molecule
Secondary pathogenic event that subsequently







Reactive microglia and astrocytes surround
amyloid plaques and secrete proinflammatory
cytokines, which are an early, prime movers in
AD evolution






leads to amyloid β (Aβ)
accumulation in brain
The triggering event and the most important
factor with highest acceptance but still not
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Table 1. Cont.
Process Remarks Related (Potential)Body-Fluid-Based Biomarkers Reference
Characteristic presence
of oxidative stress in AD
brains
Reactive oxygen species (ROS) and neuronal
apoptosis are involved not only in AD but also
other neurodegenerative diseases. Below, we
propose the oxidative stress pathways specific
to AD and involved kinases as potential
biomarkers for these processes
- -
N-Methyl-D-aspartate receptor
(NMDR)-mediated oxidative stress inducing
abnormal hyperphosphorylation of tau
Mitogen-activated protein





Aβ activates GSK-3β, which induces oxidative
stress, resulting in hyperphosphorylation of
tau, NFT formation, neuronal death, and
synaptic loss
Glycogen synthase-3β (GSK-3β) [69,70]
NMDR-mediated oxidative stress leads to
activation and phosphorylation of CREB
cAMP response element-binding
protein (CREB) [71–73]
Calcineurin activation leads to release of
intracellular Ca2+ and reduced NMDR function.
Aβ reduces NMDR function whichimpairs LTP









Morphological alterations in cerebral capillaries
and increased use of CBF and glucose
utilization have been reported in AD patients
LRP-1 [76,77]
Neurodegeneration Endpoint of different processes
Neurofilament light (NfL) [78]
Neurogranin [79]
SNAP-25 [61]
3. Most Frequently Studied Brain-, CSF-, and Blood-Derived Biomarkers of AD in Humans and
in Most Frequently Used Rat and Mouse AD Models
First, we selected the most related disease processes in AD (as described in Table 1), and within
these processes, we selected the biomarkers that currently have been identified with alteration in
body fluids such as CSF and blood in human AD patients. Thus, we ended up with a panel of nine
biomarkers, namely, Aβ1-40, Aβ1-42, P-tau, T-tau, neurofilament light (NfL), neurogranin, SNAP-25,
GFAP, and YKL-40. It should be noted that some of these compounds are not specific for AD but may
be of value by having a role in AD pathology. Second, we summarized the most frequently used rat
and mouse models in AD, to compare the information of these biomarkers in humans and in animals.
A detailed literature-searching strategy is provided in Supplementary Material 3.
Although all these biomarkers are frequently measured in AD patients, Aβ1-40 and Aβ1-42 were
the most frequently studied ones in AD animal models (as there has been much focus on the amyloid
cascade hypothesis). We wondered whether the changes in biomarkers in human and animal body
fluids would reflect those in the brain and also whether the biomarker changes in animal models
would reflect those found in AD patients. Below, we have provided information on human and animal
brain, CSF, and plasma as available for each biomarker. The information has shown to be fragmented
such that no direct comparison between animals and humans can be made, but rather a comparison of
trends could be made as a heatmap (Figure 2). Our detailed findings on actual data are summarized in
Supplementary Material 2.
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humans and different a imal models of AD. In humans, the chan e i i arker level is compared
between AD patients and healthy volunte rs. I i l els, the change in biomarker level is
compared between “old” and “young” AD ani ff t e roups) and therefore the change
during life n which AD features are assumed to progress. Literature used: [50,52, 5,78–144] (for details
on values of individual studies please ee al o Supplementary Material 2).
3.1. Aβ1-40 and Aβ1-42
Aβ, especially Aβ1-42, is the most frequently studie bio r r f . -42 and Aβ1-40 are
increased in the brains of AD patients co pared t l nteers, as well as in brains of “young”
versus “old” animals of differ nt AD rat and mouse odels.
In human CSF, Aβ1-42 levels are als f ificantly decreased in the preclinical stage
of AD [52, 7], while Aβ1-40 levels in t t e. In Tg2576 transgenic mice, also no
change in Aβ1-40 CSF level is fo bet ee iffere t age groups (3–23 months); however, there is a
significantly decrease in Aβ1-42 in the CSF in these rats. Furthermore, like in human AD, a decrease of
Aβ1-42 in CSF has been reported in older mice compared to young mice for 3xTg-AD, APPPS1, and
APP23 AD transgenic mouse models [80–82]. Following this, a decreased human CSF Aβ1-42/Aβ1-40
ratio (as widely accepted as a biomarker with better diagnostic accuracy than CSF Aβ1-42 alone for the
significantly better association with brain Aβ deposition) [83,145–147] was found. Similarly, Maia et al.,
2015 found that the CSF Aβ1-42/Aβ1-40 ratio in the APP23, APP24, and APP51 mouse models decreases
with increasing age (i.e., AD progression) [82]. However, this is not a perfect comparison, as in the
animal studies, the decrease of Aβ1-42/Aβ1-40 was with increasing age of the transgenic mice, and this
is not perfectly comparable with the cross-sectional comparisons in human studies.
Until recently, Aβ peptides measured in human plasma were considered not, or only slightly,
correlated with cerebral β-amyloidosis [57,83], and plasma Aβ1-40 concentrations were considered
to be influenced by production of platelets with Aβ1-40-loaded α-granules [147]. However, Verberk
et al., 2018 concluded that the plasma Aβ1-42/Aβ1-40 ratio has great potential as a rescreening tool
to identify AD p thology [148]. Recently, using advanced immune-precipitation coupl d with mass
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spectrometry analytical platforms, Nakamura et.al., 2018 could indeed indicate that the decreased
plasma Aβ1-42/Aβ1-40 ratio shares the trend in CSF and shows high performance when predicting
brain amyloid-β burden [149]. This result is validated by using two independent cohorts of datasets,
and both datasets contain cognitively normal individuals, individuals with MCI, and individuals
with AD dementia. Furthermore, the plasma APP669-711/Aβ1–42 ratio may differentiate between
individuals (i.e., cognitively normal individuals, those with MCI, and those with AD) with high and
low Aβ load in the brain, with a significant correlation between brain Aβ burden (as measured by
amyloid-PET) and CSF Aβ1-42 level [149]. Interestingly, the plasma levels of both Aβ1-40 and Aβ1-42 of
Tg2576 transgenic mice also significantly decrease with age (comparing different age groups between
3- and 23-month-old mice). This decrease with age was not observed in the non-transgenic control
groups, which had about 100 times lower levels of both Aβ1-40 and Aβ1-42; these levels did not change
with age (6–23 months) [84].
The ratio between P-tau and Aβ1-42 is also used. The CSF P-tau/Aβ1-42 ratio has been shown to be
a sensitive predictive diagnostic biomarker of AD and is recommended by the IWG-2 diagnostic criteria
for prodromal AD stage [11,12,150]. Moreover, the human plasma P-tau/Aβ1-42 ratio, characterized
with tau-PET, has recently been indicated to be significantly correlated with cerebral tauopathy [85].
Furthermore, a decrease in plasma Aβ1-42 has recently been indicated as a biomarker of prodromal AD
progression in patients with amnestic MCI positive subjects (based on Aβ1-42/P-tau in the CSF as well
as ApoE ε4 genotype) versus amnesic MCI AD negative subjects [151].
However, compared to the changes found in Aβ1-40 and Aβ1-42 levels measured in the CSF,
we found less consistency in the reported changes in Aβ1-40 and Aβ1-42 plasma levels in AD patients
compared to healthy controls in the different studies. Additionally, no consistency was found in
changes in plasma Aβ1-40 levels between studies using APP/PS1, 3xTg-AD, or APPPS1 mice, and
no consistency was found in plasma Aβ1-42 levels between studies using APP/PS1 and 3xTg-AD
transgenic mice. However, a decrease of plasma-derived Aβ1-42 was reported in the APPPS1 mice, and
a decrease was found in both Aβ1-40 and Aβ1-42 plasma levels in aging Tg2576 mice. No studies were
found measuring Aβ1-40 and Aβ1-42 plasma levels in rat models over time.
3.2. T-tau and P-tau
Two different forms of the microtubule-associated protein tau are measured in body fluids: total
tau (T-tau) and hyperphosphorylated tau (P-tau). P-tau has decreased capacity to stabilize microtubules.
Furthermore, in the brain, P-tau is the primary component of the NFTs [64]. In humans, the deposition
of fibrillar tau that aggregates in brain can be accessed with tau PET [152], though with limited level of
accuracy for the determination of P-tau versus T-tau. In animal studies, T-tau and P-tau levels in brain
tissue homogenate can directly be quantified, and an increase of both P-tau and T-tau levels in brains
of older animals compared to young animals was found.
In human CSF samples, P-tau and T-tau were found to be increased in sporadic AD patients
compared to healthy controls. In two animal studies, T-tau was measured in CSF. Maia et al., 2013
found an increase in T-tau in APP23 and APPPS1 mice with age [81]. Lecanu et al., 2006 reported
an increase of P-tau in CSF in aging FAB rats [86]. Furthermore, P-tau and T-tau were also found to
be mostly increased in plasma samples of 3xTg-AD compared to wild-type mice, although this was
dependent on the antibody types used [87]. This directly indicates an important point: P-tau has
many phosphorylation sites and multiple fragments in body fluids, and the results of measurements
depend on the antibody pairs used, which may hamper proper comparison of P-tau data. While the
same P-tau form (P-tau181) was measured in most of the human studies [79,85,88–91,153,154], not all
studies specify the P-tau form. In the selected animal studies, the Ser202/Thr205 form was most often
used [86,92]; furthermore, less consistency in the use of the same antibody was found in animal studies
compared to human studies.
In plasma, P-tau data are variable. Different studies measuring T-tau plasma levels reported
an increase [85,93,94] or no significant change in T-tau plasma levels in AD patients compared to
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healthy controls [94–96]. This might be related to the stage of AD or the severity of AD of the AD
subpopulation, as a T-tau increase was also not detectable in patients at MCI AD stage [93,94].
3.3. NfL
Neurofilament light (NfL) has been shown to be a dynamic cross-disease biomarker for
neurodegeneration. Although the increase of NfL in CSF is not specific for AD, it is an important
predictor of neurodegeneration in AD as well as cognitive deterioration and structural brain changes
over time [155]. In contrast to CSF T-tau and neurogranin alterations, NfL reflects neurodegeneration
independent of Aβ pathology [153]. NfL was reported to be increased in human CSF [96–98] and
plasma [78,96,99–101] of AD patients compared to healthy controls. Recently, a study has been
conducted, involving patients in a presymptomatic stage of familial AD, in which NfL levels in the CSF
(n = 187) and serum (n = 405) were found to be correlated. Interestingly, the rate of change of serum NfL
over time (i.e., log10(serum NfL) per year) could distinguish mutation carriers (i.e., highly penetrant
autosomal-dominant mutations in APP, PSEN1, or PSEN2) from nonmutation carriers, almost a decade
earlier than cross-sectional absolute NfL levels [156]. These promising results indicate the promise of
that blood-based NfL as a valuable biomarker for AD diagnosis in the preclinical stage.
NfL was detected in two transgenic mice models of AD by Bacioglu et al., 2016 [102]. In APPPS1
mice, CSF NfL increased with age: from 3 months to 12 months and to 18 months. Plasma NfL
increased accordingly. In the tau-overexpressed P301S-tau mice, CSF NfL increased with age from
2–4 months to 6–8 months and to 10–12 months until 14–16 months, as did plasma NfL [102].
3.4. Neurogranin
Neurogranin is a neural-enriched dendritic protein involved in long-term potentiation of synapses,
particularly in the hippocampus and basal forebrain. CSF neurogranin is used as a biomarker
for synapse loss and synaptic dysfunction in neurodegenerative diseases, including AD. While
Kvartsberg et al., 2019 reported a decrease of neurogranin in the brain of AD patients [103], several
other studies have reported an increase of neurogranin in CSF of AD patients [79,88,95,104–106,157].
CSF neurogranin levels did not significantly differ between AD patients and patients with Lewy
body dementia (LBD) [158]. In contrast, Mavroudis et al., 2019 found that CSF levels of neurogranin
were significantly higher in AD patients compared with cognitively normal participants, as well
as between AD patients and patients with mild cognitive impairment (MCI), So, AD patients have
higher neurogranin levels compared to MCI , and MCI has higher neurogranin levels compared to
controls, which indicates that neurogranin levels might be used to differentiate MCI patients from AD
patients [158]. In blood, no significant change in neurogranin concentration has been detected in AD
compared to controls [95,105].
No studies have reported on measuring neurogranin in the brain, CSF, or blood in the selected
animal models in a longitudinal fashion. One study using CamKII-TetOp25 mice (inducible transgenic
mice overexpressing p25, or Cdk5, which is required for normal development of the mammalian brain)
reported a significant increase of neurogranin in the CSF after 3 weeks of p25 induction [159].
3.5. SNAP-25
Massive synapse loss is another critical pathological process that occurs in the AD brain and
correlates with cognitive decline [160]. Synaptic dysfunction can occur and eventually progresses into
massive synaptic loss [161]. This process can be indicated by the decline of synaptic protein levels.
Various synaptic proteins, such as SNAP-25, synaptophysin, rab 3A (presynaptic protein), PSD-95,
synaptopodin (postsynaptic protein), synapsin 1, and chromogranin B (synaptic vesicle proteins), have
been reported to be significantly reduced in the brains of patients with AD [91,107,162–164]. Neuronal
death alone is not believed to be sufficient to explain the magnitude of synapse loss, suggesting
that synapses are selectively damaged or degenerated prior to brain cell death [165]. Reduced gene
expression patterns of genes related to synaptic vesicle trafficking have been found, which indicate that
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synapses in AD may not function effectively, even prior to visible structural alteration of neurons [166].
In contrast to the decrease of SNAP-25 found in human brains, SNAP-25 is found to be increased in the
CSF of AD patients compared to age-matched controls [91,108–110]. No studies were found measuring
the difference of SNAP-25 in the blood of AD patients compared to healthy controls.
Additionally, no studies were found measuring SNAP-25 in brain, CSF, or blood samples in the
selected animal models. Reports about synaptic loss in transgenic mice models of AD are mainly
based on histological studies. For instance, dendritic spine loss was reported in 8-month-old PDAPP
mice and 4.5-month-old Tg2576 mice [167]. Early synaptic loss was identified in hippocampus of
3–4-month-old J20 mice bearing APPswe and APPind mutations. In the brain of these mice, the levels
of synaptophysin, PSD95, synaptotagmin, and homer significantly decreased, preceding the deposition
of senile plaques [168]. Dendritic spine loss around Aβ plaques began approximately at 3 months of
age in APP/PS1 mice [169]. Age-dependent loss of synaptophysin, synaptotagmin, PSD-95, and homer
immunoreactivity was reported in the hippocampus of 4-month-old APP/PS1 mice [168]. Although the
immunoactivity of certain synaptic proteins has been used to evaluate synaptic loss in these histological
studies, the corresponding body-fluid-based changes of these proteins have not been measured.
3.6. GFAP
Gliosis is a nonspecific phenomenon that occurs in response to injuries to the brain and involves
the activation and proliferation of glial cells. In AD, gliosis is marked by an increase in activated
microglia and reactive astrocytes near the sites of Aβ plaques [58]. It is widely accepted that the
interaction of microglia with fibrillary Aβ leads to microglia and astrocyte activation, which results in
the production of chemokines, neurotoxic cytokines, and reactive oxygen and nitrogen species that are
deleterious to the brain [170]. Moreover, it has been shown that reactive astrocytes play an additional
role in AD by their contribution to an overall amyloid burden in the brain, given the wide expression of
APP, BACE1, and γ-secretase in astrocytes [58]. Glial fibrillary acidic protein (GFAP) is an established
indicator for astrocyte activation. GFAP is found to be increased in postmortem human brain tissue
samples of AD patients [111], but no significant change is found in postmortem cerebellar brain tissue
compared to age-matched controls [112]. An increase in GFAP with age was found in brains from
APP/PS1 [113], 3xTg-AD [114], and APPPS1 [115] transgenic mouse models. The same was reported for
the McGill-R-Thy1-APP [116] and TgF344-AD [117] transgenic rat model, as well as the FAB rat [86].
Furthermore, GFAP is increased in the CSF of AD patients [98,118]. GFAP levels in serum have also
been reported to be increased in serum from AD patients compared to non-neurodegenerative controls,
and the increase of serum GFAP correlated with the Mini-Mental State Examination score. Moreover,
serum GFAP might be used to discriminate between AD and behavioral variant of frontotemporal
dementia [119].
Body-fluid-based markers for gliosis in AD mouse and rat models are not reported.
3.7. YKL-40
YKL-40, also called chitinase-3-like 1 (CHI3L1), is a glycoprotein expressed by different cells (such
as astrocytes and macrophages) and, although its function is not yet completely understood, is linked
to inflammation [120,171]. YKL-40 was found to be increased in the brains of AD patients compared to
healthy controls [120]. Furthermore, increased levels of YKL-40 are found in CSF [50,55,89,98,120] and
in plasma [50,121] of AD patients compared to healthy controls. Interestingly, Wenström et al., 2015
found increased levels of YKL40 in the CSF of AD patients, compared to the nondemented control group,
but not in patients with Lewy body disease or Parkinson’s disease [55]. Moreover, the increase of CSF
YKL-40 has also been observed in preclinical (based on clinical dementia rating (CDR) or Mini-Mental
State Examination (MMSE) score) AD patients and AD subjects with MCI [50,89]. No studies were
found measuring YKL-40 in brain, CSF, or blood samples in the selected animal models.
Overall, for animal studies, researchers tend to seek for “direct answers” of the AD-like pathology
in the brain; however, we believe that there is an underestimation of the value in also including
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body-fluid-based biomarkers of the animals to understand how AD pathology in brain is reflected in
body fluids.
4. Emerging Techniques and Body-Fluid-Based Biomarkers
In the near future, emerging biomarkers, measured in different body fluids, might provide
additional valuable information on processes occurring in the early onset and progression of AD. These
include, but are not limited to, extracellular vesicles (EVs); microRNAs; and proteomic-, metabolomic-,
and lipidomic-based body fluid biomarkers.
4.1. MicroRNAs as Body-Fluid-Derived Biomarkers for AD
MicroRNAs (miRNAs) are a group of biomarkers that can be found in different body fluids,
like CSF, blood, and saliva. These small (about 20 nucleotides), noncoding RNAs play a role in
many different biological processes. Importantly, miRNAs are known to be conserved across species.
Accumulating evidence suggests that alterations in the miRNA networks could contribute to the
pathology of AD, or can at least be used as an early indication of the development of AD. Results
from recent studies in humans suggest that a number of specific miRNAs are differently expressed in
disease conditions, of which some are thought to be involved in the regulation of key genes in AD,
including APP and BACE-1.
A subset of miRNAs seems to be specifically altered in the AD brain, including miR-29, miR-15,
miR-107, miR-181, miR-146, miR-9, miR-101, miR-106, miR-125b, and miR-132. All were independently
validated in two or more studies [60,172]. Furthermore, several large-scale genome-wide profiling
studies have been performed, demonstrating that, beside the brain, miRNA levels in blood and CSF are
also differently expressed in AD patients, compared to age-matched healthy volunteers [173]. Several
miRNAs are indicated to be putatively proinflammatory, including miR-9, miR-125b, miR-146a, and
miR-155. The expression levels of these miRNAs are increased in both postmortem brain extracellular
fluid (brain ECF) and the CSF of postmortem AD patients [173]. The levels of miRNAs, including
miR-137, miR-9, miR-29a, and miR-29b, were found to be significantly reduced in plasma of probable
AD patients with a Mini-Mental State Examination score of 23–28 [174].
Recent studies on miRNA expression changes in AD patients suggest the potential of
body-fluid-based miRNAs to assist the early diagnosis of AD. However, many of these studies
were cross-sectional, with one measurement per patient only, limiting the usage of miRNAs as
biomarkers when assessing AD progression. Longitudinal observations of miRNA alterations in AD
animal models might provide complementary information of pathology-associated differences in
miRNA levels during the progression of AD, particularly in an early stage. Genome-wide analysis of
the brain miRNA signature in an APP/PS1dE9 mouse model was investigated by Luo et al., 2014 [175].
In this study, nine miRNAs, namely miR-99b-5p, miR-7b-5p, miR-7a-5p, miR-501-3p, miR-434-3p,
miR-409-5p, miR-331-3p, miR-138-5p, and miR-100-5p, showed consistent changes at 2, 4, 6 and
12 months of age in the APPswe/PS1dE9 mouse model. Another study showed 37 miRNAs that
are consistently changed in the cerebral cortex of APP/PS1dE9 mice, among which 17 miRNAs are
downregulated. These include miR-20a, miR-29a, miR-125b, miR-128a, and miR-106b [176], which
are linked to AD based on information of human AD studies. miR-106b is increased in the cerebral
cortex of 3- and 6-month-old APP/PS1dE9 mice but decreased in 9-month-old mice (although still
remaining slightly higher compared to the level of miR-106b in 3-month-old mice) [177]. This indicates
that miRNA expression patterns may change over time.
Furthermore, the plasma miRNA profile was investigated at different timepoints during the AD-like
pathology progression in 3xTg-AD mice [178]. Plasma samples were obtained from 2–3-month-old
and 14–15-month-old 3xTg-AD and wild-type (WT) mice. No significant differences in miRNA levels
were detected between WT and transgenic mice at the young (2–3 months) age, while age-related
significant changes in miRNAs were observed in both WT and transgenic mice, with some of these
changes being specific for 3xTg-AD mice. Nineteen miRNAs show similar change over time of both
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WT and transgenic mice. These include family members of let-7, miR-30, and the miR-17-92 cluster and
its paralogs. A group of miRNAs, including miR-132, miR-138, miR-146a, miR-146b, miR-22, miR-24,
miR-29a, miR-29c, and miR-34a, show significant changes in plasma levels only in the transgenic
group. These age-dependent changes are of interest as they could consequently derive from AD
pathology progression in this mouse line. The plasma miRNA profile has also been studied over time
in the APP/PS1dE9 mice model. At 4 months, when these mice are in the prepathological stage of
AD, a significant decrease in expression of miR-200b-3p, miR-139-5p, and miR-27b-3p was observed,
together with a significant increase of miR-205-3p and miR-320-3p expression [179]. At 8 months,
when amyloidosis is apparent in these mice, the expression of a different set of miRNAs is altered,
with an increase in 4 miRNAs (miR-140-3p, miR-486-3p, miR-339-5p and miR-744-5p) and a decrease
in miR-143-3p and miR-34a-5p. At 15 months, expression of miR-339-5p and miR-140-3p remained
significantly increased, suggesting a sustained increase in expression of these two miRNAs over time.
4.2. Proteomic Body-Fluid-Based Biomarkers
Proteomics is a multidisciplinary, technology-driven science that focuses on the analysis of
proteomes, i.e., the proteins of a biological system, their structures, interactions, post-translational
modifications, and, in particular, the changes in their levels and their modifications as the result of
specific diseases or external factors [180].
Although untargeted proteomic analysis can provide us with unbiased body fluid protein panels
that have potential diagnostic value in AD, issues around quantification and reproducibility should be
considered. Thus, an alternative approach in the proteomic study was advocated where the subjects
involved in the studies are grouped to a continuous variable such as brain atrophy, rate of cognitive
decline, Aβ burden, and CSF biomarker level (so-called “endophenotype discovery”) [181]. Based on
this, Shi et al., 2018 summarized the “endophenotype discovery” for plasma proteomic biomarkers in
AD and eight most replicated protein biomarkers were selected [181]. However, it should be noted
that for the discovery of robust (i.e., reliable and quantifiable) proteomic biomarkers for AD, the
comparability of data from multiple large studies across heterogeneous populations is needed; this
remains challenging, as has been addressed by Carlyle et al., 2018 [182].
In case of AD, several CSF- and blood-based proteomics analyses have been conducted by
comparing the proteome profiles of these body fluids of AD patients to the control groups to collect
information about gene products involved in AD, i.e., alterations in protein levels and post-translational
modifications. Several proteomic targets have been discovered that displayed significant alteration
in the CSF of AD subjects compared to the control group [183–185]. In these studies, a certain
consistency was observed in the alteration of apolipoproteins in the CSF of AD patients, suggesting
that a pronounced reduction of pro-apolipoproteins might be a potential CSF-based biomarker of
AD. In blood, however, only few putative blood-based protein biomarkers could be replicated in
independent studies. This was concluded by a large-scale replication check for 94 of the 163 candidate
biomarkers from 21 published studies in plasma samples from 677 subjects [186].
In AD animal models, proteomic biomarker profiles from the brain hippocampus homogenate
of ADLPAPT mice [187], APP/PS1 mice, and ApoE4 knock-in mice models [188] have been identified
with age-dependent alterations; many of the differentially expressed proteins were identical at
presymptomatic stage of the mice, earlier than the formation of Aβ plaque. However, body-fluid-based
proteomic biomarkers in AD animal models are still missing. It would be interesting to also investigate
these markers in CSF and plasma of the animal AD models to relate these body-fluid-based to
brain-tissue-based proteomic markers and the pathological changes of the brain. Furthermore, these
biomarkers can be traced throughout the lifespan of animals as well as the disease progression, and
this could provide insights in refinement of biomarkers in human body fluids.
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4.3. Metabolomic and Lipidomic Body-Fluid-Based Biomarkers
Metabolomics is one of the latest systems biology approaches where multiple platforms are
utilized to measure levels of small-molecule metabolites in biological samples. Metabolic signatures
are unique to an individual wherein perturbations in metabolite levels may inform on the disease
state and underlying mechanisms of the disorder [189]. Given their close association with the host’s
phenotypes, the profile of metabolites demonstrates the current physiological state of a cell and is the
end result of the upstream biological information that flows from genome over to transcriptome and
proteome to metabolome [190].
In 2018, Hurtado et al. reported the state of the art in AD-related metabolomic biomarker evidence
based on studies on metabolomics and lipidomics in AD [191]; in 2019, several novel targets were
reported as potential body-fluid-based biomarkers in AD, where it was found that kynurenine pathway
metabolites and primary fatty amides showed great significance in their alterations in AD subjects
compared to the controls [192,193]. Multiplatform metabolomics has emerged as an essential tool for
the identification of potential AD biomarkers in different human body fluids, and many potential
biomarkers have been discovered in the last decade. However, only a few of these have been validated.
Moreover, fellow researchers in this area expressed concerns about the consistency of the proteomics,
metabolomics, and lipidomics studies and called for interlaboratory validations [190]. So, while this is
an emerging field of high interest, it suffers from interlaboratory differences and reproducibility issues.
However, different laboratories have extensively validated their metabolic and lipidomic platforms,
and series of studies all using the same platform will definitely provide relevant data on changes in
AD onset and progression.
4.4. Extracellular-Vesicle-Based Biomarkers
EVs include, from small to large size, exosomes, microvesicles, and apoptotic bodies; are secreted
from different cells in the body; and contain unique molecular information regarding their cell of origin.
They are released into the extracellular environment and are known to play a role in intercellular
communication between cells in close proximity, as well as between distant cells. This, together with
the fact that EVs have been found in many different body fluids including blood, urine, and CSF,
has raised interest in the use of EVs as a source for the discovery of novel biomarkers. It should be
noted that the methodologies to isolate EVs, the techniques used for quantification of EVs, and the
techniques to quantify their characteristics and content are all crucial for the data obtained, and good
comparisons of data currently published are not yet possible [194] (unpublished data of our group).
So, what is described below should be interpreted given these drawbacks
Several studies indicate that AD patients could be distinguished from cognitive normal controls
based on the (synaptic) protein cargo from neural-derived EVs extracted from plasma. These biomarkers
would reflect AD pathology up to 10 years before the clinical onset of AD [195]. Different types
of AD biomarkers were investigated by Goetzl et al., showing that Aβ and tau proteins increased
along with AD progression [195], while synaptic markers significantly declined [196,197]. In these
studies, the EV-based lysosomal proteins, brain insulin resistance factor, and cellular survival factors
appeared to be useful in distinguishing between control and AD progression in multiple stages of the
disease [198,199]. However, the work of the Goetzl group has not yet been reproduced by others, while
their L1CAM work was done in what they claimed as early stages of AD (i.e., not specified/defined),
all of which means that the value of their work remains to be seen.
In addition, EVs originating from the Central Nervous System (CNS) were found in plasma,
containing the AD-related biomarkers Aβ1-42, P-tau, and T-tau. These EVs were found to identify
patients converting from MCI to dementia [200]. Moreover, Gui et al., 2015 reported that the miRNA
profile in CSF-derived EVs was altered in AD. The mRNA transcripts of APP, Tau, NfL, DJ-1/PARK7,
fractalkine and neurosin were altered, and long noncoding RNAs (RP11-462G22.1 and PCA3) were
also found to be differentially expressed in CSF-derived EVs [201]. Overall, these studies demonstrate
the potential of EV-based biomarkers in the early stages of AD.
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Still, only a few studies investigated EV-based biomarkers in AD transgenic mouse and rat models.
One study, by Eitan et al., 2016, reported higher levels of Aβ1-42 and Aβ1-40 in plasma-derived EVs of
six APP/PS1 mice and five 3xTgAD mice compared to nine age-matched WT control mice. The absolute
levels of Aβ1-42 and Aβ1-40 in plasma-derived EVs in these transgenic mice were lower compared
to the levels of these markers found in EV-depleted plasma, while the ratio of Aβ1-42/Aβ1-40 was
significantly higher in EVs [202]. This indicates that EV-based biomarker alterations can be different
from body-fluid-based alterations and that plasma-derived EVs might provide biomarkers with higher
sensitivity than whole-plasma-derived biomarkers.
5. Discussion and Conclusions
The number of currently existing and emerging pathophysiological hypothesis, mechanisms, theories,
and processes related to AD is high and is still increasing. This indicates that AD is a very complex and
multifactorial disease. An important problem is that we do not have a cure or treatment for AD. Another
problem is that the disease cannot be diagnosed in an early stage. Currently, we lack information and
understanding of processes in the onset and early stage of the disease. As such, we lack an early diagnosis
and treatment option in the early phase of AD. This highlights the need to find adequate, preferably
body-fluid-based biomarkers of AD. Currently, the biomarkers that are mostly measured in human studies
are Aβ, P-tau, T-tau, neurogranin, SNAP-25, GFAP, YKL-40, and especially NfL. Additionally, there is a
high volume of animal research, in which the emphasis has mostly been on Aβ.
For early diagnosis and treatment of AD, we first need to solve the problem of the gap in the
knowledge and understanding of the onset and early phase of AD. miRNAs and EVs, together
with proteomic, metabolomic, and lipidomic body-fluid-based biomarkers are emerging as (early)
biomarkers of AD as well as other diseases. miRNAs are conserved across species, which makes it
easier to extrapolate findings between humans and animal models of AD. However, as a drawback, it is
hard to assess whether a change in microRNA expression level is a result or a cause of AD. Moreover, a
single microRNA can target multiple genes, and one gene can be targeted by different microRNAs.
Furthermore, while omic technics show great potential in the discovery of new biomarkers in AD,
a drawback here is the current lack of consistency and reproducibility, which indicates that omic
markers in AD need to be further validated. Then, the use of EVs combined with the measurement
of EV-associated and non-EV-associated miRNAs together with techniques like metabolomics and
lipidomics show great promise for the detection of novel biomarkers in body fluids and for the
collection of new information to increase our understanding of the pathogenesis of AD. Here, the
drawback is in the multiple methodologies in isolating and characterizing EVs, which influence the
data obtained and thereby make comparisons between the data difficult.
For the biomarkers that have been investigated in brain, CSF, and blood, the changes in disease
stage are rather different (Figure 2), and so they are not directly related. This indicates that body fluids
might not directly provide mechanistic information on the disease stage, and in humans it might be
difficult to study the interrelationships and time-dependencies of the biomarkers. Therefore, we need
different approaches for more mechanistic understanding of early AD and its progression.
We believe that the problem of the gap in knowledge and understanding of the onset and early
phase of AD cannot be solved by human studies alone. This is for the simple reasons that it is too
costly and too time-intensive to measure many compounds in human samples, let alone imaging
studies, in well-controlled and longitudinal studies in the ageing human population, in which a small
percentage will actually develop AD. Thus, there is the need for alternative approaches to obtain a
useful understanding on the relation between the changes in (body fluid) biomarkers and (early) AD
stage. In our view, animal studies could be helpful.
An ideal animal model that exhibits all features of human AD does not exist. Current animal
AD models are at best to be regarded as reductionist tools, as the majority of the animal models
represent familial AD while most AD patients have sporadic AD (although a few non-transgenic rat
models of AD have been developed [117]). However, animal models of AD may still be of value to
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gain understanding on the pathological processes involved in AD if enough similarities exist between
animal AD models and human AD. To that end, an overview is given on associated and most frequently
measured biomarkers in brain, CSF, and blood of human AD and animal models of AD. Where possible,
the trend in changes of these biomarkers is assessed and summarized in a heat map (Figure 2).
Although a direct comparison between human (familial and sporadic) AD and (mostly genetic)
animal AD models cannot be made, a majority of similar trends are observed in brain, CSF, and blood
for human AD stage and animal AD model life stage, assuming that a later stage in life of the AD
animal represents a later stage in AD. Despite the current limitation of exact knowledge on AD stage
in humans and in animals, we see many similarities. This makes us believe that animal models of
AD have a good potential to provide information that can be useful for also better understanding the
(early) processes in AD.
While we all strive for the reduction/replacement in the use of animals, we should realize two
things. (1) The problem of AD is too big not to make all efforts possible to diagnose AD in an early
stage, where the disease might be halted or even reversed. (2) AD is too complex to be understood
from single-biomarker and single-timepoint measurements. Therefore, we must study this complex
disease in a very systematic research manner including multiple biomarker measurements at multiple
sites in the body (fluids and tissue) in a longitudinal fashion under well-defined conditions, applying
advanced mathematical modeling (according to the Mastermind Research approach [26]) to unravel
the processes and their interactions (Figure 3). Ideally, composite biomarker panels will reflect all
processes that occur in AD in a stage-dependent manner. However, it should be noted that due to the
small sample size of brain ECF, CSF, and blood that can be obtained from rats and especially mice,
sampling as well as detecting compounds and EVs in these body fluids is challenging.
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Figure 3. The recently developed human CNS drug distribution model is an example of application of
the Master Research Approach [26]. The model is developed on the basis of animal research, and now
CNS drug distribution in humans can be predicted without the need of experimental animals [203,204].
Recently, we have shown that the strategic use of animals and the collection of smart data have led
to a mathematical model that can adequately predict drug distribution into multiple physiologically
relevant compartments of the CNS, not only in animals, but also in humans. It should be noticed that
CNS drug distribution is also the result of multiple processes and their interdependencies. The CNS
drug distribution model has been developed using systematic research in experimental animals by
varying conditions, measuring drug concentrations at multiple locations in the CNS, and making
differences between drug and body properties explicit, such that the body properties of the rat could
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be replaced by human body properties. Our CNS drug distribution model can now replace the use of
animals and directly predict CNS drug distribution in humans on the basis of plasma pharmacokinetics
and drug properties [203,204]. This indicates a much better and efficient use of animals.
Thus, for AD, longitudinal early-life-studies can be performed in both transgenic and
non-transgenic animal AD models and their control littermates, on a much shorter time scale than
in humans, while measurements can also be taken at multiple timepoints at multiple body sites
(including body fluids) and finally also in the brain, to relate to currently known brain markers of AD.
This anticipated approach is depicted in Figure 4.
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Figure 4. Anticipated approach to study and understand the processes in AD progression. Longitudinal,
multiple-biomarker, multiple-body-site measurements in AD animals (and their control littermates—not
shown here) should be able to reveal processes and their interdependencies in AD and in normal ageing
as stage (T1, Tx, Tn)-dependent “composite biomarker panels”, leading to insights that are AD-specific
to be targeted as therapy.
Altogether, in our view, strategic and well-controlled animal studies are needed to fill the crucial
knowledge gap, especially on the processes involved in the onset and early stage of AD. Thus, as much
as possible in individual animals, multiple (putative) biomarkers should be measured at multiple body
sites, including body fluids, to understand their interdependencies and time-dependencies in AD
onset and progression (according to the Mastermind Research approach). By this approach, systematic
research can also be performed on combinations of conditions, such as comorbidities.
Once we have such understanding, we will have a good basis for defining (multiple) targets to be
modified by therapeutic approaches in order to halt the disease or even be able to reverse the disease
in its early stage into a healthy condition again.
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